Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,287 GBX | +0.33% | +1.06% | +15.53% |
May. 14 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
May. 14 | ASTRAZENECA : Buy rating from JP Morgan | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.53% | 239B | |
+31.06% | 688B | |
+30.35% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+10.16% | 210B | |
-8.14% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study